Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


COVID-19 Antiviral Agents and COVID-19 Rebound
  • CME
  • CE

Expert discussion of landmark clinical trials of COVID-19 antivirals for nonhospitalized patients and the COVID-19 rebound phenomenon.
person default
Jason Gallagher, PharmD
Emily Heil, PharmD, MS, BCIDP, AAHIVP
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Registered Nurses: 0.75 Nursing contact hours
Pharmacists: 0.75 contact hours (0.075 CEUs)
Released: November 22, 2022 Expiration: November 21, 2023

In this episode, Jason Gallagher, PharmD, and Emily Heil, PharmD, MS, BCIDP discuss landmark clinical trials of COVID-19 antivirals for nonhospitalized patients and COVID-19 rebound phenomenon, including:

  • EPIC-HR study of nirmatrelvir plus ritonavir
  • PINETREE study of remdesivir
  • MOVe-OUT and Panoramic studies of molnupiravir
  • COVID-19 rebound in treated and untreated patients

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Appropriately advise patients and colleagues regarding evolving best practices in clinical care for COVID-19
  • Identify new advances in COVID-19 therapeutics and vaccines that warrant prompt integration into patient care
  • Integrate novel, evidence-based strategies for COVID-19 treatment and prevention into clinical practice

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


Jason Gallagher, PharmD

Clinical Professor
School of Pharmacy
Temple University
Clinical Pharmacy Specialist
Infectious Diseases
Temple University Hospital
Philadelphia, Pennsylvania

Jason Gallagher, PharmD: consultant/advisor/speaker: Entasis, Merck, Qpex, Shionogi, Spero; researcher: Merck.
Emily Heil, PharmD, MS, BCIDP, AAHIVP

Associate Professor
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Infectious Diseases Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland

Emily Heil, PharmD, MS, BCIDP, AAHIVP, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Target Audience

This program is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who provide care for patients with or at risk of COVID-19.


The goal of this activity is to enable healthcare professionals to promptly update their clinical management strategies to reflect the latest insights by providing expert filtering and interpretation of the burgeoning scientific literature on COVID-19.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-297-H01-P

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 22, 2022, through November 21, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Gilead Sciences, Inc.

Related Content

This downloadable PDF reviews a treatment pathway for nonhospitalized patients with COVID-19, from Clinical Care Options (CCO), Practicing Clinicians Exchange (PCE), and ProCE

Renslow Sherer, MD Released: January 17, 2023

Dr Stephaun Elite Wallace on COVID-19 inequities in BIPOC communities and strategies to minimize these disparities, from Clinical Care Options (CCO), Practicing Clinicians Exchange (PCE), and ProCE

Stephaun Elite Wallace, PhD, MS Released: January 17, 2023

Clinical Care Options (CCO) podcast with Drs. Jens Lundgren and Barbara Rath on acute COVID-19 and long COVID in Europe.

Jens D. Lundgren, MD, DMSc Barbara Rath, MD, PhD, HDR Released: January 13, 2023

Drs Jens Lundgren and Barbara Rath on acute COVID-19 and long COVID in Europe, from Clinical Care Options (CCO)

Jens D. Lundgren, MD, DMSc Barbara Rath, MD, PhD, HDR Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: January 11, 2023 Expired: January 10, 2024

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings